{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:18:05Z","timestamp":1761823085989},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2003,12,1]],"date-time":"2003-12-01T00:00:00Z","timestamp":1070236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Prostate Cancer"],"published-print":{"date-parts":[[2003,12]]},"DOI":"10.3816\/cgc.2003.n.022","type":"journal-article","created":{"date-parts":[[2008,9,11]],"date-time":"2008-09-11T01:07:06Z","timestamp":1221095226000},"page":"147-152","source":"Crossref","is-referenced-by-count":21,"title":["Complications of Androgen-Deprivation Therapy for Prostate Cancer"],"prefix":"10.3816","volume":"2","author":[{"given":"Jeffrey M.","family":"Holzbeierlein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik P.","family":"Castle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Brantley","family":"Thrasher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CGC.2003.n.022_bib1","first-page":"293","article-title":"Studies on prostate cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma on the prostate","volume":"1","author":"Huggins","year":"1941","journal-title":"Cancer Res"},{"key":"10.3816\/CGC.2003.n.022_bib2","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJM199912093412401","article-title":"Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer","volume":"341","author":"Messing","year":"1999","journal-title":"N Engl J Med"},{"key":"10.3816\/CGC.2003.n.022_bib3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJM199707313370502","article-title":"Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin","volume":"337","author":"Bolla","year":"1997","journal-title":"N Engl J Med"},{"key":"10.3816\/CGC.2003.n.022_bib4","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/00007611-199809000-00010","article-title":"Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer","volume":"91","author":"Schow","year":"1998","journal-title":"South Med J"},{"key":"10.3816\/CGC.2003.n.022_bib5","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/0090-4295(92)90401-H","article-title":"Treatment of castration-induced menopausal symptoms with low dose diethylstilbestrol in men with advanced prostate cancer","volume":"40","author":"Miller","year":"1992","journal-title":"Urology"},{"key":"10.3816\/CGC.2003.n.022_bib6","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/S0022-5347(17)32530-2","article-title":"Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma","volume":"152","author":"Karling","year":"1994","journal-title":"J Urol"},{"key":"10.3816\/CGC.2003.n.022_bib7","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0022-5347(17)32835-5","article-title":"A prospective comparison of treatments for symptomatic hot flushes following endocrine therapy for carcinoma of the prostate","volume":"152","author":"Smith","year":"1994","journal-title":"J Urol"},{"key":"10.3816\/CGC.2003.n.022_bib8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0090-4295(89)90385-3","article-title":"Flushing. Long-term side effect of orchiectomy in treatment of prostatic carcinoma","volume":"33","author":"Charig","year":"1989","journal-title":"Urology"},{"key":"10.3816\/CGC.2003.n.022_bib9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/pros.2990070210","article-title":"Measurement of skin blood-flow and water evaporation as a means of objectively assessing hot flushes after orchidectomy in patients with prostatic cancer","volume":"7","author":"Frodin","year":"1985","journal-title":"Prostate"},{"key":"10.3816\/CGC.2003.n.022_bib10","first-page":"1319","article-title":"Management of hot flushes due to endocrine therapy for prostate carcinoma","volume":"10","author":"Smith","year":"1996","journal-title":"Oncology (Huntingt)"},{"key":"10.3816\/CGC.2003.n.022_bib11","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0090-4295(99)00370-2","article-title":"Transdermal estrogen in the treatment of hot flushes in men with prostate cancer","volume":"55","author":"Gerber","year":"2000","journal-title":"Urology"},{"issue":"suppl 5","key":"10.3816\/CGC.2003.n.022_bib12","first-page":"132","article-title":"DepoProvera therapy for hot flashes associated with hormonal treatment of advanced carcinoma of the prostate","volume":"159","author":"Ellsworth","year":"1998","journal-title":"J Urol"},{"key":"10.3816\/CGC.2003.n.022_bib13","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0022-5347(01)61789-0","article-title":"Acupuncture treatment of vasomotor symptoms in men with prostatic carcinoma: a pilot study","volume":"161","author":"Hammar","year":"1999","journal-title":"J Urol"},{"key":"10.3816\/CGC.2003.n.022_bib14","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0022-5347(17)40081-4","article-title":"Treatment of post-orchiectomy hot flashes with transdermal administration of clonidine","volume":"143","author":"Parra","year":"1990","journal-title":"J Urol"},{"key":"10.3816\/CGC.2003.n.022_bib15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0029-7844(97)00597-8","article-title":"The effect of dietary soy supplementation on hot flushes","volume":"91","author":"Albertazzi","year":"1998","journal-title":"Obstet Gynecol"},{"key":"10.3816\/CGC.2003.n.022_bib16","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1200\/JCO.1998.16.2.495","article-title":"Prospective evaluation of vitamin E for hot flashes in breast cancer survivors","volume":"16","author":"Barton","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CGC.2003.n.022_bib17","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00007611-199904000-00013","article-title":"Progressive prostate cancer associated with use of megestrol acetate administered for control of hot flashes","volume":"92","author":"Sartor","year":"1999","journal-title":"South Med J"},{"key":"10.3816\/CGC.2003.n.022_bib18","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJM199408113310602","article-title":"Megestrol acetate for the prevention of hot flashes","volume":"331","author":"Loprinzi","year":"1994","journal-title":"N Engl J Med"},{"key":"10.3816\/CGC.2003.n.022_bib19","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<825::AID-CNCR13>3.0.CO;2-N","article-title":"A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181","volume":"88","author":"Dawson","year":"2000","journal-title":"Cancer"},{"key":"10.3816\/CGC.2003.n.022_bib20","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1200\/JCO.1998.16.7.2377","article-title":"Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors","volume":"16","author":"Loprinzi","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CGC.2003.n.022_bib21","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/00005392-199907000-00024","article-title":"Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer","volume":"162","author":"Quella","year":"1999","journal-title":"J Urol"},{"key":"10.3816\/CGC.2003.n.022_bib22","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(00)03403-6","article-title":"Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial","volume":"356","author":"Loprinzi","year":"2000","journal-title":"Lancet"},{"key":"10.3816\/CGC.2003.n.022_bib23","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S0022-5347(17)35034-6","article-title":"Transdermal clonidine for ameliorating post-orchiectomy hot flashes","volume":"151","author":"Loprinzi","year":"1994","journal-title":"J Urol"},{"key":"10.3816\/CGC.2003.n.022_bib24","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1023\/A:1007164319067","article-title":"\u201cHot flush,\u201d an unpleasant symptom accompanying antiandrogen therapy of prostatic cancer and its treatment by cyproterone acetate","volume":"32","author":"Cervenakov","year":"2000","journal-title":"Int Urol Nephrol"},{"key":"10.3816\/CGC.2003.n.022_bib25","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0302-2838(03)00379-8","article-title":"Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment","volume":"44","author":"Morote","year":"2003","journal-title":"Eur Urol"},{"key":"10.3816\/CGC.2003.n.022_bib26","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1210\/jcem-69-3-523","article-title":"Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling","volume":"69","author":"Stepan","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"10.3816\/CGC.2003.n.022_bib27","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1097\/01.ju.0000059281.67667.97","article-title":"Fracture risk following bilateral orchiectomy","volume":"169","author":"Melton","year":"2003","journal-title":"J Urol"},{"key":"10.3816\/CGC.2003.n.022_bib28","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S8756-3282(99)00117-9","article-title":"The structural basis of bone fragility in men","volume":"25","author":"Seeman","year":"1999","journal-title":"Bone"},{"key":"10.3816\/CGC.2003.n.022_bib29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF00298427","article-title":"Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens","volume":"57","author":"Eriksson","year":"1995","journal-title":"Calcif Tissue Int"},{"key":"10.3816\/CGC.2003.n.022_bib30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1210\/jc.86.6.2787","article-title":"Bone loss in men with prostate cancer treated with gonadotropin releasing hormone agonists","volume":"86","author":"Stoch","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.3816\/CGC.2003.n.022_bib31","first-page":"314a","article-title":"Prospective serial measurements of bone mineral density (BMD) in prostate cancer patients without bone metastases treated with intermittent androgen suppression (IAS)","volume":"18","author":"Higano","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CGC.2003.n.022_bib32","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0090-4295(02)02006-X","article-title":"Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer","volume":"61","author":"Smith","year":"2003","journal-title":"Urology"},{"key":"10.3816\/CGC.2003.n.022_bib33","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1056\/NEJM199410203311604","article-title":"Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man","volume":"331","author":"Smith","year":"1994","journal-title":"N Engl J Med"},{"key":"10.3816\/CGC.2003.n.022_bib34","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","article-title":"Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer","volume":"345","author":"Smith","year":"2001","journal-title":"N Engl J Med"},{"key":"10.3816\/CGC.2003.n.022_bib35","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1002\/1097-0142(20010615)91:12<2238::AID-CNCR1254>3.0.CO;2-2","article-title":"Low bone mineral density in hormone naive men with prostate carcinoma","volume":"91","author":"Smith","year":"2001","journal-title":"Cancer"},{"key":"10.3816\/CGC.2003.n.022_bib36","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1210\/jc.84.10.3431","article-title":"Osteoporosis in men","volume":"84","author":"Bilezikian","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.3816\/CGC.2003.n.022_bib37","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM200008313430902","article-title":"Alendronate for the treatment of osteoporosis in men","volume":"343","author":"Orwoll","year":"2000","journal-title":"N Engl J Med"},{"issue":"suppl 2","key":"10.3816\/CGC.2003.n.022_bib38","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1081\/CNV-120014886","article-title":"The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate","volume":"20","author":"Lipton","year":"2002","journal-title":"Cancer Invest"},{"key":"10.3816\/CGC.2003.n.022_bib39","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","article-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer","volume":"169","author":"Smith","year":"2003","journal-title":"J Urol"},{"key":"10.3816\/CGC.2003.n.022_bib40","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/(SICI)1097-0142(20000101)88:1<6::AID-CNCR3>3.0.CO;2-D","article-title":"Oral bisphosphonates: A review of clinical use in patients with bone metastases","volume":"88","author":"Major","year":"2000","journal-title":"Cancer"},{"key":"10.3816\/CGC.2003.n.022_bib41","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2165\/00003495-200161060-00010","article-title":"Zoledronic acid","volume":"61","author":"Cheer","year":"2001","journal-title":"Drugs"},{"key":"10.3816\/CGC.2003.n.022_bib42","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0093-7754(01)90232-5","article-title":"Dosing regimens and main adverse events of bisphosphonates","volume":"28","author":"Body","year":"2001","journal-title":"Semin Oncol"},{"key":"10.3816\/CGC.2003.n.022_bib43","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/0026-0495(90)90190-N","article-title":"Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer","volume":"39","author":"Tayek","year":"1990","journal-title":"Metabolism"},{"key":"10.3816\/CGC.2003.n.022_bib44","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/S0090-4295(96)00381-0","article-title":"Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study","volume":"48","author":"Higano","year":"1996","journal-title":"Urology"},{"key":"10.3816\/CGC.2003.n.022_bib45","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jc.87.2.599","article-title":"Changes in body composition during androgen deprivation therapy for prostate cancer","volume":"87","author":"Smith","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.3816\/CGC.2003.n.022_bib46","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1046\/j.1464-410X.1997.00234.x","article-title":"Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade","volume":"79","author":"Strum","year":"1997","journal-title":"Br J Urol"},{"key":"10.3816\/CGC.2003.n.022_bib47","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1464-410X.2002.02917.x","article-title":"Altered cognitive function in men treated for prostate cancer with luteinizing hormone releasing hormone analogues and cyproterone acetate: a randomized controlled trial","volume":"90","author":"Green","year":"2002","journal-title":"Br J Urol"},{"key":"10.3816\/CGC.2003.n.022_bib48","first-page":"45","article-title":"Andropause and testosterone supplementation for cognitive loss","volume":"23","author":"Tan","year":"2002","journal-title":"J Androl"},{"key":"10.3816\/CGC.2003.n.022_bib49","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0959-8049(00)00084-8","article-title":"Fatigue in patients with prostate cancer receiving hormone therapy","volume":"36","author":"Stone","year":"2000","journal-title":"Eur J Cancer"}],"container-title":["Clinical Prostate Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154003521170035X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154003521170035X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T22:58:53Z","timestamp":1557788333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154003521170035X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,12]]}},"alternative-id":["S154003521170035X"],"URL":"https:\/\/doi.org\/10.3816\/cgc.2003.n.022","relation":{},"ISSN":["1540-0352"],"issn-type":[{"value":"1540-0352","type":"print"}],"subject":[],"published":{"date-parts":[[2003,12]]}}}